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ABSTRACT  
Objective: To formulate, optimize and evaluate 5-fluorouracil loaded liquorice crude protein nanoparticles for sustained drug delivery using Box-
Behnken design.  
Methods: 5-fluorouracil (5-FU) loaded liquorice crude protein (LCP) nanoparticles were prepared by desolvation method using ethanol-water (1:2 
ratio), Tween-80 (2%v/v) as stabilizing agent and gluteraldehyde (8% v/v) as cross linking agent. The optimization of prepared nanoparticles was 
carried out using Box-Behnken design with 3 factors 2 levels and 3 responses. The independent variables were A)5-FU concentration B)LCP 
concentration and C) sonication time while the responses were R1) Drug entrapment efficiency R2) Drug loading efficiency and R3) Particle size. 
The correlation between factors and responses were studied through response surface plots and mathematical equations. The nanoparticles were 
evaluated for FTIR, physicochemical properties like particle size and zeta potential by Photon correlation spectroscopy (PCS) and surface 
morphology by TEM. The entrapment efficiency, drug loading efficiency and in vitro drug release studies in PBS pH 7.4 (24 h) were carried out. The 
observed values were found to be in close agreement with the predicted value obtained from the optimization process. 
Results: 5-fluorouracil loaded LCP nanoparticles were prepared by desolvation method, the optimization was carried out by Box-Behnken design 
and the final formulation was evaluated for particle size (301.1 nm), zeta-potential (-25.8mV), PDI(0.226), with entrapment efficiency (64.07%), 
drug loading efficiency (28.54%), in vitro drug release (65.2% in 24 h) respectively. The formulated nanoparticles show Higuchi model drug release 
kinetics with sustained drug delivery for 24 h in pH7.4 buffer.  
Conclusion: The results were proved to be the most valuable for the sustained delivery of 5-Fluorouracil using liquorice crude protein as carrier. 5-
FU–LCP nanoparticles were prepared using Tween-80 as stabilizing agent and gluteraldehyde as cross-linking agent to possess ideal sustained drug 
release characteristics. 
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INTRODUCTION 
The formulation of nanoparticle-based drug delivery systems is 
rapidly developing due to their great targeting potential. These 
materials are mainly used in oncology for early detection of 
malignancy and precise localization of cancer therapeutics without or 
with minimal adverse effects to the somatic tissues [1]. Drugs, 
vaccines, nutrients and cosmetics are protected by the use of properly 
designed carriers. Nanoparticles exert its site-specific drug delivery by 
bypassing the reticuloendothelial system, making use of enhanced 
permeability and retention effect and tumour specific targeting. The 
formation of nanoparticles and physicochemical parameters such as 
pH, monomer concentration, ionic strength as well as surface charge, 
particle size and molecular weight are important factors for drug 
delivery. A major problem in chemotherapy, which is multidrug 
resistance can be reversed by these nanoparticles.  
Biodegradable protein nanoparticles have attained much interest in 
the past few years due to their wide variety of desirable properties 
like low toxicity [2]. Nanoparticles derived from green particles 
(natural proteins) are easily adaptive to surface modifications and 
targeting ligands. Biomolecule carrier-mediated drug delivery 
suggests a number of design opportunities for the delivery of a 
particular drug, with greater therapeutic effect [3]. It is proven that 
the encapsulation of anti-cancer agents in nanometer and 
micrometer particle size range can control their release, and 
nanotechnology could be a better alternative to increase the life 
expectancy of cancer patients.  
5-Fluorouracil (initially 7-12 mg/kg IV for 4 d) [4] is a cell cycle–
phase-specific broad-spectrum anti neoplasic agent. 5-FU exerts its 
cytotoxic activity by interfering with nucleoside metabolism thus 
competing for the enzyme that is essential for the synthesis of 
thymidine, an important substrate for DNA synthesis. Due to its high 
rate of metabolism in the body, a continuous administration of high 
dose is required for the maintenance of therapeutic serum 
concentration, which leads to severe toxic effects. 
The present study aims to formulate, optimize and characterize 5-
fluorouracil loaded liquorice crude protein nanoparticles for 
sustained drug delivery using Box-Behnken design. 
Protein-based nanoparticles are notable due to their relative safety, 
easy preparation and size monitoring. They are also susceptible to 
various modifications to incorporate functional and targeting 
capabilities. A protein-based nanocarrier system that has made an 
impact in cancer therapy is the albumin-bound Paclitaxal 
(Ambraxane, ABI008) by FDA for metastatic breast cancer. A 
number of studies have given evidence that albumin accumulates in 
solid tumours making it a potential carrier for targeted delivery of 
antitumor drugs [5-7]. They are deemed as ideal compounds for 
nanoparticle preparation because of their amphiphilicity, allowing 
them to interact well with both the drug and solvent. Protein-based 
drug delivery systems have a great advantage of conventional drug 
delivery systems due to their biodegradability, non-antigenicity and 
excellent biocompatibility to improve the therapeutic properties of 
anti-cancer drugs [8]. 
In this present study, nanoparticles were prepared with crude 
protein extract obtained from Liquorice (Glycerrhiza glabra L.) roots 
(Fabaceae) as carrier molecule and with broad-spectrum anticancer 
drug 5–fluorouracil as a model drug [9-11]. 
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The model drug used in the present study is 5-Fluorouracil, which is 
a hydrophilic pyrimidine analogue and is one of the broad 
spectrums anti-cancer drugs used in the treatment of various 
malignancies. Due to its short half-life and various side effects, its 
medical applicability is limited. 
Many studies as per the literature review, shows 5-fluorouracil 
nanoparticles prepared with BSA (Bovine serum albumin) shows 
good targeting properties compared to free drugs. As an alternative 
to blood-derived albumin and recombinant human serum albumin, 
natural/green protein derived from liquorice crude protein (LCP), 
which are albuminoidal in nature, has been used in this study for the 
sustained delivery of 5-fluorouracil for the first time [12, 13]. 
MATERIALS AND METHODS 
Drugs and chemicals 
5-fluorouracil (5-FU, purity 99%) was obtained from Sigma–Aldrich 
Chemical Company Ltd. Liquorice fine powder was purchased from 
Indus valley Bioorganic (100% natural pure liquorice powder). 
Liquorice crude protein extract was prepared in phosphate buffer 
(pH 7.2) and all the reagents used in the present study were of 
analytical grade. 
Preparation of liquorice crude protein (LCP) extract 
Finely powdered liquorice root was extracted in phosphate buffer 
(pH 7.2) in 1:5 (w/v) ratio and 100Mm NaCl in order to stabilize the 
protein. After 24 h under refrigeration (4 °C), coarse filtration and 
centrifugation were done [14]. Then proteins were precipitated by 
salting out method. Impurities were removed by changing pH and 
dialyzed to remove the excess salt for 2 d with intermittent changing 
of buffer. The dialyzed liquid was freeze-dried to get crude freeze 
dried liquorice protein extract. Sherif EA Badr studied the protein 
content in different extracts of liquorice, which was confirmed by 
the analytical report of the present study, which showed 33.53% 
crude protein using Kjeldahl method in PBS pH 7.2. Lowry assay 
method was conducted to quantify the total protein content of the 
freeze-dried extract after dialysis [15]. 
Protein estimation 
Protein was estimated by the method as described by Lowry. The 
blue colour developed by the reduction of the Phosphomolybdic-
Phosphotungstic components in the Folin-ciocalteau reagent by the 
amino acids Tyrosine and Tryptophan present in the protein plus 
the colour developed by the biuret reaction of the protein with the 
alkaline cupric tartarate are measured in the Lowry method. 
Materials used are 2% Sodium carbonate in 0.1N Sodium Hydroxide 
(Reagent A), 0.5% Copper sulphate (CuSO4.5H2O) in 1% potassium 
sodium tartarate (Reagent B), Alkaline copper solution: About 50 ml of 
reagent A was mixed with 1 ml of reagent B prior to use (Reagent C), 
Folin Ciocalteau reagent (Reagent D): Phenol reagent is mixed with 
an equal volume of water before use, Protein Stock Solution–About 
50 mg of Bovine serum albumin (BSA) was dissolved in 50 ml of 
standard flask, Working standard: About 10 ml of the stock solution 
was diluted to 50 ml with distilled water in a standard flask (One ml 
of this solution contains 200µg protein). 
Sample preparation 
About 0.5 mg of sample was taken and dissolved in 500 µl distilled 
Phosphate buffer 
Procedure for estimation of protein: About 0.2 ml of sample extract 
was taken. Volume was made up to 1 ml in all the test tubes. A tube 
with 1 ml of water serves as the blank. 5 ml of reagent C was added to 
each tube, including blank. It was then mixed well and allowed to 
stand for 10 min. Then 0.5 ml of reagent D was added, mixed well and 
incubated at room temperature in the dark for 30 min. Blue colour 
developed was read at 660 nm. A standard graph was plotted using 
BSA as standard and amount of protein in the sample was calculated. 
Formulation of 5–Fluorouracil loaded LCP nanoparticles 
5FU loaded LCP nanoparticles were formulated using the 
desolvation method to yield the nanoparticles with lower particle 
size, more uniform size distribution and high entrapment of 5-FU. 
For the preparation of nanoparticles 5-FU was added to the LCP 
solution (1:2) in water, adjusted the pH to 8-8.4. Afterward, the 
solution was desolvated by the addition of ethanol at the rate of 1 ml 
per minute under stirring, followed by the addition of Tween 80 
(2%w/v) with constant stirring in a magnetic stirrer of 600 rpm 
until the suspension becomes turbid. One drop of glutaraldehyde 
solution (8% v/v) was added as a cross-linking agent and continued 
stirring for another 4 h. Ethanol was evaporated and Nanoparticles 
formed were sonicated for 40 min (ice bath) and homogenized in a 
high-pressure homogenizer. The drug-loaded nanoparticles were 
then separated by centrifugation (10,000 x 2 min) and lyophilized to 
get the 5-FU loaded LCP nanoparticles [16-18]. 
Optimization of prepared nanoparticles  
Box-behnken design 
A Box-Behnken statistical design with 3 factors, 2 levels and 17 runs 
was selected for the study using Design-Expert 11.0.2 software trial 
version (Stat-Ease Inc, Minneapolis, USA). This design is suitable for 
exploring quadratic response surfaces and constructing second 
order polynomial models. The primary screening studies revealed 
that the LCP concentration, Drug concentration and sonication time 
as significant factors [19-21]. 
The polynomial equation generated by the experimental design is as 
follows:  
R=C0+C1A+C2B+C3C+C4AB+C5AC+C6BC+C7A2+C8B2+C9C
Where R is the dependent variable, C
2 
0 is the intercept C1–C9
Evaluation of 5-fluorouracil loaded LCP nanoparticles 
 are the 
regression coefficients, and A, B, C are the independent variables. 
Particle size, surface charge and morphology 
Particle size and size distribution of nanoparticles were determined by 
dynamic light scattering (DLS) using a particle size analyzer (Malvern 
Instrument Ltd, UK). Samples were diluted with double distilled water 
and measured at the temperature of 25 °C and a scattering angle of 90°. 
To determine the zeta potential, Nanoparticles were dispersed in de-
ionized water and taken in disposable zeta cells and measured by laser 
Doppler anemometry using Zetasizer (Malvern Instrument Ltd, UK) [26]. 
The experiments were performed in triplicate and results are presented 
as mean±SEM. The morphological features of lyophilized 5-FU-LCP 
Nanoparticles were examined by Transmission electron microscopy 
(TEM) (JSM-7600F, JEOL, USA) [22-25]. 
Transmission electron microscopy-(TEM) 
The morphology, structure and particle size of 5-FU LCP nanoparticles 
were examined by Transmission Electron Microscopy by JOEL model 
JSM-6390 LV an Electronic Transmission Microscope at 70 KV. In this 
method, nanoparticles were dispersed onto a surface of a copper grid 
sample holder. Upon drying the grids, which is then stained with 1% 
w/v phosphotungstic acid for 120 seconds and dried at room 
temperature. These samples were then placed in sample holders and 
probed with Transmission Electron Microscopy. The image was then 
photocopied, in which objects were visualized in order of angstroms. 
Drug entrapment efficiency (% DEE) 
For the determination of entrapment efficiency, accurately weighed 
5-FU loaded nanoparticles (10 mg) were added to 10 ml of 
phosphate buffer and centrifuged at 5000 rpm for 1 hour using 
REMI R-8C centrifuge. The supernatant solution was filtered, diluted 
suitably and absorbance was measured using JASCO V-630 UV 
spectrophotometer at 266 nm. Concentration of drug in the 
supernatant was calculated using the standard calibration data. The 
entrapment efficiency was calculated using the formula. 
Entrapment efficiency (%) = drug  totalofAmount 
 x100lesnanoparticin  drug Entrapped
-Equation 1 
Drug loading efficiency (% DLE) 
Evaluation of drug loading efficiency of LCP nanoparticles were done 
by taking the UV-Visible absorbance of initial 5-FU content in the 
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solution and the residual 5-FU content in the collected supernatants 
at 266 nm. The amount of 5-FU was determined by a calibration 
curve method and the calibration plot was generated from a series 
of 5-FU solutions with different concentrations. 
Drug loading efficiency (%) = lesnanopartic ofAmount 
100 x lesnanopartic in the drug Entrapped
-Equation 2 
Drug excipients compatibility study by FTIR spectroscopy 
5 FU-LCP mixtures was mixed with IR grade Potassium bromide (KBr) 
and made into a transparent and homogenous pellet using pressed pellet 
technique. FTIR scanning was performed using Agilent Technologies 
CARY 630 FTIR. FTIR spectra were obtained in the range of 400-4000 
cm-1
In vitro drug release study 
 under operational conditions. The spectrum obtained and peaks 
were studied and compared with the reference spectrum. 
To study the release kinetics, a sample of nanoparticles equivalent to 5 
mg of drug was dissolved in 2 ml buffer solution and taken in a dialysis 
bag with both ends clipped (dialyzing membrane-150, molecular 
weight cut off 12000-14000 Dalton) were kept in 100 ml of phosphate 
buffer saline pH 7.4 under continuous stirring at 60 rpm at 37±0.5 °C. 
After different time intervals, 2 ml of sample volume were withdrawn 
from dissolution media and replaced with the fresh buffer to maintain 
sink conditions. The samples were filtered with a membrane filter 
(0.22µ) and the amount of drug released was quantified by using UV 
Spectrophotometer at a wavelength 266 nm against blank and 
cumulative drug release was calculated [27] 
Release kinetics 
The mechanism of 5-FU release from the nanoparticles was studied 
by fitting the in vitro release data into kinetic models such as zero 
order, first order, Higuchi and Korsmeyer–Peppas model. 
Stability studies 
The 5-FU loaded LCP nanoparticles suspension was stored at 4 °C, 
25 °C, and 40 °C respectively for 6 mo and the effect on particle size, 
drug loading efficiency and drug release were studied. 
RESULTS AND DISCUSSION 
Estimation of protein by lowry assay method 
As per Lowry assay method, total protein content of the freeze dried 
sample of LCP extract is shown in table 1. 
 
Table 1: Protein content in LCP extract as per lowry assay method 
Sample Protein(μg/ml) (µg/mg) or ppm Percentage % 
1 91.25 456.25 0.04 
1a 92.25 460.12 0.04 
2 89.5 447.5 0.04 
2a 94.75 473.25 0.04 
 
Optimization using box-behnken design 
The independent variables were A) 5-FU Concentration (% w/v) B) 
LCP Concentration (%w/v) C) Sonication time (min) and the 
dependent variables were R1) Drug entrapment efficiency (%) R2) 
Drug loading efficiency (%) and R3) Particle size (nm). The goal of 
optimization was to maximize entrapment efficiency and drug 
loading efficiency and to minimize particle size (table 2). Each factor 
was tested at two levels, upper limit and lower limit. Based on 
optimization in Box-Behnken design, contour plots and response 
surface plots were studied for the effects of independent variables 
on dependent variables with maximum desirability. 
 
Table 2: Variables and their constraints in the box-behnken design 
Variables Constraints 
Independent variables Lower limit Upper limit 
A: 5FU Concentration (%w/v)  1  3  
B: LCP Concentration (%w/v)  2  6  
C: Sonication time (mins)  20  40  
Dependent variables Goal 
R1: Drug Entrapment Efficiency (DEE) (%) Maximise  
R2: Drug Loading Efficiency (DLE) (%) Maximise  
R3: Particle size (nm) Minimise  
Therefore a 3 factor 2 levels based Box-Behnken design with 17 formulations was applied to understand the impact of independent variables on 
dependent variables (table 3). 
 
Table 3: Formulations of 5FU-LCP nanoparticles 





C: Sonication time Drug entrapment efficiency (DEE) Drug loading 
efficiency (DLE) 
Particle size 
 %w/v %w/v min % % nm 
1 2 6 20 74.76±0.41 34.47±0.95 293.77±4.23 
2 3 2 30 68.13±0.32 36.23±0.88 321.85±1.66 
3 1 2 30 75.07±0.44 38.86±0.67 286.84±3.06 
4 1 6 30 72.31±0.39 37.28±0.79 309.01±1.25 
5 2 4 30 62.47±0.21 20.56±1.61 346.65±3.74 
6 2 6 40 71.27±0.37 34.53±1.32 299.56±2.14 
7 1 4 20 78.82±0.32 33.83±0.54 270.89±3.62 
8 2 2 40 74.19±0.40 35.86±0.61 277.89±7.59 
9 2 4 30 63.61±0.35 21.38±1.49 346.65±4.50 
10 3 4 20 71.22±0.49 31.08±1.38 307.98±3.11 
11 2 2 20 77.33±0.67 36.16±0.24 271.78±6.85 
12 1 4 40 76.59±0.42 35.89±2.05 275.48±3.64 
13 2 4 30 63.19±0.39 21.32±1.74 348.72±4.73 
14 2 4 30 63.14±0.40 20.56±1.32 346.56±1.44 
15 3 4 40 67.87±0.36 30.89±1.95 310.55±2.56 
16 2 4 30 61.29±0.43 22.13±1.22 346.65±3.82 
17 3 6 30 64.69±0.56 34.07±0.64 344.01±1.32 
*Data are expressed as mean±SD (n=3) 
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Statistical optimization by response surface methodology  
The Quadratic model was chosen as the best fit model based on 
regression coefficient values (R2
 
) very close to 1 (table 4) and 
based on p-values<0.05, which deemed the model to be 
significant. 
Table 4: Fit statistics showing R2
Response 
 values 
R Adjusted R2 Predicted R2 2 
R1: Drug entrapment efficiency (%) 0.9930 0.9839 0.9736 
R2: Drug loading efficiency (%) 0.9961 0.9912 0.9726 
R3: Particle size (nm) 0.9995 0.9989 0.9957 
 
Response 1: Drug entrapment efficiency (%) 
The effect of entrapment efficiency on 5-FU conc, LCP conc and 
sonication time were studied. 
The EE (%) increases with an increase in 5-FU conc and sonication 
time were observed (fig. 1). 
The predicted R2 value of 0.9839 was found to be in reasonable 
agreement with an adjusted R2
R1 = 62.74-3.86A-1.46125B-1.52625C-0.17AB-0.28AC-0.0875BC+ 
3.27375A
 value of 0.9736, The Model F-value of 
109.68 implies that the model is significant. 
2+4.03625B2+7.61125C
After observing p-values of coefficients in the polynomial equation, 








Fig. 1: Contour and response surface plot of factors against drug entrapment efficiency (R1) 
 
Response 2: drug loading efficiency (%) 
The effect Drug loading efficiency of on formulation factors was 
studied, the RSM plots shows direct relation between factors and 
responses (fig. 2). 
The predicted R2 value of 0.9726 was found to be in reasonable 
agreement with adjusted R2
R2 = 21.19-1.69875A-0.845B+0.20375C-0.145AB-0.5625AC+ 
0.09BC+6.54375A
 value of 0.9912, The Model F-value of 
200.72 implies that the model is significant. 
2+8.87625B2+5.18875C
After observing the p-values of coefficients in the polynomial 
equation, it is seen that terms A, B, A
2 
2, B2, C2 are significant. 
Velraj et al. 





Fig. 2: Contour and response surface plot of factors against drug loading efficiency (R2) 
 
Response 3: particle size (nm) 
Effect of particle size on variables showed a direct relationship with 
5-FU conc and LCP conc and an inverse relationship with sonication 
time as per fig. 3. The predicted R2 value of 0.9989 was found to be 
in reasonable agreement with an adjusted R2
R3 = 347.046+17.7713A+10.9988B+2.38253C-0.0025AB-0.55BC-
0.0800592BC-13.0717A
 value of 0.9957, The 
Model F-value of 1590.06 implies that the model is significant. 
2-18.5468B2-42.7493C
After observing the p-values of coefficients in the polynomial 
equation, it is seen that terms A, B, C, A
2 
2, B2, C2
Based on the above pre-optimization parameters the 5-FU loaded 
LCP nanoparticles were prepared. 
 are significant. 
The optimum levels of formulation factors for an optimized 
formulation based on the Box-Behnken design were 3% w/v of drug 
5-FU, 4% w/v of LCP, 40 min sonication time with predicted values 
of 310.87 nm for particle size, 67.95% for DEE%, and 30.86% for 
DLE%.  
Particle size, PDI, zeta potential 
The mean particle size of nanoparticle formulation was in the range 
of nm. Formulation of 5-FU LCP nanoparticles showed relatively 
small particle size, i.e.270.89 nm to 348.72 nm. Poly dispersivity 
index (PDI) of 0.226 (fig. 4) and zeta potential of-33.2mV (fig. 5) 
were in the good range. 
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Fig. 3: Contour and response surface plot of factors against particle size (nm) (R3) 
 
 
Fig. 4: Particle size analysis and polydispersity index of formulated 5-FU loaded LCP nanoparticles 
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Fig. 5: Zeta potential of formulated 5-FU loaded LCP nanoparticles 
 
TEM analysis of the prepared nanoparticles revealed a 
homogeneous solid matrix structure without any aggregation (fig. 
6). Particle size distribution analysis by zetasizer showed that the 
mean average of the prepared nanoparticles was 301.1 nm and 




Fig. 6: TEM analysis of formulated 5-FU loaded LCP nanoparticles 
 
Fourier transform infrared spectroscopy (FTIR) studies 
FTIR spectra of pure 5-FU (fig. 7), LCP Extract (fig. 8) and the 
mixture of 5-FU and LCP Extract (fig. 9) are shown below. The 
principal IR absorption peaks of 5-FU were all observed in the 
spectra of 5-FU as well as 5-FU–LCP mixture. These observations 




Fig. 7: FTIR spectrum of 5-FU 
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Table 5: FTIR data of 5-FU 
Wave number (cm-1 Functional group  )  
3065.23  N-H stretching  
1651.75  C=O stretching  
1428.57  C-N stretching  
1243.21  In-plane C-H bending  
 
 
Fig. 8: FTIR spectrum of LCP extract 
 
Table 6: FTIR data of LCP Extract 
Wave number (cm-1 Functional group  )  
3276.74  -NH Stretch.  
2928.54  -COOH stretch  
1660  C=O bond stretching in peptide 
1241.86  In-plane C-H bending 
 
 
Fig. 9: FTIR spectrum of 5-FU and LCP extract 
 
 
Fig. 10: Drug release profile of 5-FU from 5-FU loaded LCP nanoparticles 
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Table 7: FTIR data of 5-FU and LCP extract 
Wavenumber (cm-1 Functional group  )  
3276.81  -NH Stretch.  
2958.55  CH stretch  
1634.05  -CO Stretch. 
1239.84  Secondary amine NH bend 
 
In vitro drug release from nanoparticles 
The percentage release of the cumulative 5-fluorouracil from the 
optimized formula after a different time period is shown as a graph 
(fig. 10). After the initial burst release for 45 min, the release rate of 
5-fluorouracil from the nanoparticles slowed down. After 24hours, 
the amount of accumulated 5-fluorouracil in PBS was calculated to 
be 65.2% of the entrapped drug [13]. 
 
Table 8: Data for drug release profile 













*Data are expressed as mean±SD (n=3) 
 
In vitro kinetics studies of 5-FU LCP nanoparticles 
 
Fig. 11: In vitro drug release kinetics 
 
Table 9: Release kinetics 
pH Zero-order First-order Higuchi Korsmeyer–Peppas 
R R2 R2 R2 N 2 
7.4 0.806 0.912 0.979 0.975 0.562 
  
Drug release kinetics 
Drug release kinetics of the selected formulation was assessed by 
zero-order, first-order, Higuchi and Korsmeyer-Peppas mechanisms 
and the relevant plots are shown in fig. 11 and the corresponding 
data in table 9. It is evident that the in vitro drug release of 5-FU 
from LCP nanoparticles at pH 7.4 was best explained by Higuchi’s 
model as the plot showed the highest linearity with the regression 
value of R2 value 0.979. Korsmeyer-Peppas plot (R2
The optimized formulation was prepared using the desolvation 
method and the actual values of the responses were 301.1 nm for 
 value 0.975) 
with n value= 0.562 proved that the release follows Anomalous non-
Fickian diffusion controlled mechanisms. 
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particle size, 64.07% for drug entrapment efficiency, and 28.54% for 
drug loading efficiency. The actual values of responses were found to 
be in very close agreement to the predicted values which indicated 
the validity of the Box-Behnken design. 
Stability studies 
The 5-FU loaded LCP Nanoparticles suspension was stored at 4 °C, 
25 °C, and 40 °C, respectively. The drug loading and encapsulation 
efficiency decreased sharply at 40 °C after 10 d. On the contrary, at 4 
°C or at 25 °C, the drug loading and encapsulation efficiency 
decreased slowly during the test time. However, the nanoparticles at 
25 °C were aggregated after 6 mo storage, while at 4 °C the 
nanoparticles were not. Moreover, at 4 °C the encapsulation 
efficiency and drug loading of nanoparticles decreased less than the 
other storage conditions (25 °C and 40 °C). The drug loading 
decreased only 1% after 6 mo storage at 4 °C. Therefore, the 
nanoparticles were suitable to be stored at 4 °C. Generally, proteins 
are best stored at ≤ 4  °C. Storage at room or higher temperature 
often leads to protein degradation and/or inactivity. 
In recent years, the targeted delivery of anti-cancer drugs 
encapsulated in natural polymers, such as proteins of natural origin 
(green protein) has gained much attention as these proteins can act 
as carriers in targeting drugs to the particular sites. In the present 
study, an attempt was made to develop a nanoparticulate sustained 
delivery system for 5-Fluorouracil with LCP extract by simple 
coacervation/desolvation method. FTIR studies were carried out to 
find the possible interaction between the drug and the LCP extract 
and the fig. 9 shows there was no interaction between the drug and 
LCP extract. Optimization was done using Box Behnken design with 
3 factors and 3 responses, which enables us to obtain spherical 
discrete spheres with a size ranging from 270.89 nm to 348.72 nm 
and the surface morphology was revealed by TEM analysis showed 
spherical particles with distinct borders (fig. 6). Among the different 
batches the formulation F15 was selected as ideal formulation, after 
considering the drug loading capacity, drug entrapment efficiency 
and in-vitro drug release with minimum particle size. The optimized 
formula was reformulated with 3%w/v 5-FU, 4%w/v LCP with 
sonication time of 40 min, after characterizing the particles we 
studied the in vitro drug release profile of formulated nanoparticles 
in PBS pH 7.4 (fig. 10) for 24 h with an drug entrapment efficiency of 
64.07%, drug loading efficiency of 28.54% and particle size of 301.1 
nm with very slight variations between optimized and observed 
values. The particle size was found to be reduced with sonication 
time due to the presence of Tween 80, which acts as a solubilizing 
agent. Release kinetics showed the drug release follows the Higuchi 
Non-Fickian diffusion-controlled (R2= 0.979) with n value of 
Korsmeyer-Peppas equation 0.562 (R2
The in vitro drug release profile of the formulated 5-fluorouracil 
liquorice crude protein nanoparticles has two distinct phases-(i) 
Initial burst release phase (for about 45 min)–Must be due to the 
dissolution and diffusion of the drug that was poorly entrapped in 
the polymer (protein) matrix. (ii) Slower and continuous phase–
After the initial burst release, this phase is attributed to the diffusion 
of the drug localized from the core of the nanoparticles. By 
comparing the in vitro drug release of 5-fluorouracil alone, and BSA 
5-fluorouracil nanoparticles, this pattern of drug release has been 
reported before [5]. 
=0.975). Protein content in 
the LCP extract was confirmed by the Lowry assay method. The 
Study reveals the fact that Liquorice crude protein extract in 
phosphate buffer (7.2) contains albuminoidal protein as per the 
study by Li-jing Ke, for aconitine encapsulation with licorice protein. 
T. Mallamma studied the 5-Fluorouracil loaded HSA (Human Serum 
Albumin) nanoparticles for controlled drug delivery [23-30]. 
CONCLUSION 
5–FU loaded Liquorice crude protein nanoparticles were formulated 
by desolvation/simple coacervation technique after extraction of 
LCP from the powdered liquorice root in PBS at pH 7.2. The present 
study provides a new approach and material for the application of 
active phytochemicals with much less safety concerns. By comparing 
the drug release from 5-fluorouracil nanoparticles alone, which is 
very fast, a sustained release of drug profile was obtained in the 
present study. With advanced techniques for purification and 
isolation of particular protein from the crude extract, and with 
proper selection of a dissolution medium at different pH, a sustained 
release pattern as that of albumin nanoparticles is attainable. The 
results of this study clearly indicate that there is a potential for nano 
particulate delivery of 5-fluorouracil liquorice crude protein (as 
carrier) from liquorice extract in minimizing drug induced toxicity. 
However extensive studies in terms of chronic toxicity, 
pharmacokinetic and pharmacodynamic are needed before 
establishing nanoparticle mediated green protein encapsulated 
delivery of this drug.  
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